Pharma Two B develops clinically differentiated and value-added products, based on approved drugs, with complementary and synergistic effects and optimized delivery profiles, providing high clinical value and shorter regulatory pathways (US 505b2 approach). The company develops products in the therapeutic areas of Parkinson's disease (PD) and Cancer. Pivotal phase IIb with our lead product P2B001 for early stage Parkinson’s disease (PD) was successfully completed, meeting all endpoints.

Contact Us